Azafaros
Noémie Hurst has been working in the pharmaceutical industry since 2009. Noémie started as a Trainee as a research associate in a lab specialized in immunology at Actelion in 2009. In 2010, they became a Trainee as a research associate in a lab specialized in inflammation at Actelion. In 2012, they took on the role of Jr Clinical Pharmacologist at Actelion, where they were responsible for the scientific part of phase I studies, responsible for the PK part of phase III studies, and involved in the preparation of the clinical pharmacology part for a NDA submission. From 2017 to 2022, they worked at Roche as a Clinical Science Lead and Sr Clinical Scientist. Currently, they are a Senior Clinical Project Scientist at AZAFAROS B.V.
Noémie Hurst received their Doctor in Pharmacy (PharmD) from the University of Strasbourg, Faculty of Pharmacy in 2013, having studied Pharmacy from 2005-2013. From 2009-2012, they completed their Master of Science (MSc) in Biotechnology at ESBS.
This person is not in any offices
Azafaros
Azafaros is developing new treatment options to help patients with rare metabolic disorders. Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential.